| Jingyan Wang,Linzhi Zhang,Xiaoming Peng,Yun Zhao,Lin Zhou. Evaluation of the safety and efficacy of glucocorticoid therapy for hyperbilirubinemia in patients with hepatocellular carcinoma who have undergone transcatheter arterial chemoembolization. Oncol Transl Med, 2020, 6: 81-86. |
| Evaluation of the safety and efficacy of glucocorticoid therapy for hyperbilirubinemia in patients with hepatocellular carcinoma who have undergone transcatheter arterial chemoembolization |
| Received:December 26, 2019 Revised:April 16, 2020 |
| View Full Text View/Add Comment Download reader |
| KeyWord:glucocorticoid; primary liver cancer; hyperbilirubinemia;transcatheter arterial chemoembolization (TACE |
| Author Name | Affiliation | E-mail | | Jingyan Wang | The Fifth Medical Center of PLA General Hospital | wangjingyan.yan@163.com | | Linzhi Zhang | The Fifth Medical Center of PLA General Hospital | | | Xiaoming Peng | The Fifth Medical Center of PLA General Hospital | | | Yun Zhao | The Fifth Medical Center of PLA General Hospital | | | Lin Zhou | The Fifth Medical Center of PLA General Hospital | lindagery302@163.com |
|
| Hits: 6629 |
| Download times: 7268 |
| Abstract: |
| Objective The aim of this study was to analyze the safety and efficacy of glucocorticoid treatment for
hyperbilirubinemia in patients with hepatocellular carcinoma (HCC) who have undergone transcatheter
arterial chemoembolization (TACE).
Methods We conducted a retrospective analysis of the clinical data of 198 patients with HCC who
were admitted to The Fifth Medical Center of PLA General Hospital from June 2014 to August 2019
and underwent TACE therapy. The patients were divided into glucocorticoid (GCC) treatment group and
control group. Standard liver-protecting procedures were used in both groups. The treatment group also
received intravenous injections of methylprednisolone sodium succinate for 3–5 days. Reduction in bilirubin
concentration, mean duration of hospitalization, and complications were compared between the two groups
to investigate the safety and efficacy of GCCs for treatment of hyperbilirubinemia after TACE treatment.
Results Bilirubin concentrations were significantly lower in the treatment group than in control group
on days 3 and 5 after GCC/conventional liver-protecting treatment (P < 0.05). The treatment group had
significantly shorter durations of total post-surgery hospitalization, and recovery time than the control group
(14.5 ± 4.6 days vs. 17.5 ± 6.6 days, P < 0.001; 9.2 ± 3.3 days vs. 11.8 ± 5.4 days, P = 0.001; 7.0 ± 3.3
days vs. 9.3 ± 4.6 days, P < 0.001). No GCC-associated complications were detected in the treatment
group.
Conclusion Short-term use of GCCs to treat hyperbilirubinemia in patients with HCC who have
undergone TACE is safe and associated with rapid decline in bilirubin concentration and shorter hospital
stay compared with patients who did not receive GCCs. |
| Close |